Refractory Myelodysplastic Syndrome Clinical Trials
2 recruiting trials for Refractory Myelodysplastic Syndrome. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Refractory Myelodysplastic Syndrome clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Mayo Clinic (1), Fred Hutchinson Cancer Center (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Biospecimen Collection (procedure, 2 trials), followed by Bone Marrow Aspiration, Bone Marrow Biopsy.
Track Refractory Myelodysplastic Syndrome trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called...
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of...
This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine,...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Refractory Myelodysplastic Syndrome, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Refractory Myelodysplastic Syndrome, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Refractory Myelodysplastic Syndrome, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.